Oxlumo Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The growth in the historic period can be attributed to improved genetic screening for primary hyperoxaluria, limited historical treatment alternatives, advancements in rna-based therapeutics, increased awareness of rare renal disorders, regulatory approvals for orphan drugs.

The growth in the forecast period can be attributed to expansion of gene-silencing therapeutic pipelines, increasing investment in rare disease drug development, rising adoption of precision nephrology treatments, growing global access to genetic diagnostics, enhanced long-term disease management strategies. Major trends in the forecast period include increasing adoption of rna interference therapies, rising focus on genetic kidney disorders, expansion of precision medicine for rare diseases, growing use of subcutaneous targeted therapies, enhanced monitoring of metabolic disease progression.

The growing focus on personalized medicine is expected to drive the growth of the Oxlumo market in the future. Personalized medicine refers to a healthcare approach that tailors treatment plans and therapies based on an individual’s genetic makeup, lifestyle, and environmental factors to achieve the most effective outcomes. The rise in personalized medicine is driven by advancements in genomics, which enable more targeted and effective treatments based on a person’s genetic profile and lifestyle. Oxlumo (lumasiran) contributes to personalized medicine by targeting specific genetic mutations in individuals with primary hyperoxaluria type 1 (PH1), a rare genetic disorder. This allows for tailored treatment that reduces oxalate production and prevents kidney damage based on the patient's unique genetic profile. For example, in February 2024, the Personalized Medicine Coalition (PMC), a US-based organization, reported that the FDA approved 16 new personalized treatments for patients with rare diseases in 2023, up from six in 2022. Therefore, the increasing focus on personalized medicine is fueling the growth of the Oxlumo market.

The increasing prevalence of primary hyperoxaluria is expected to drive the growth of the Oxlumo market in the coming years. Primary hyperoxaluria is a rare genetic disorder characterized by excessive oxalate production, leading to the formation of kidney stones, kidney damage, and other complications. The prevalence of primary hyperoxaluria is driven by genetic mutations that impair the body’s ability to metabolize oxalate, causing its accumulation and potential kidney damage. Oxlumo helps manage primary hyperoxaluria by inhibiting the enzyme alanine-glyoxylate aminotransferase (AGT), reducing oxalate production and minimizing the risk of kidney damage. For example, in October 2024, Kidney Care UK, a UK-based nonprofit organization, reported that hyperoxaluria affects approximately 1 in 500,000 individuals in the UK, with Type 1 being the most common form, accounting for 80% of cases. Types 2 and 3 each represent around 10% of cases. Additionally, in October 2023, the National Center for Biotechnology Information (NCBI), a US-based national library of medicine, published epidemiological data from Europe indicating that PH1 has an estimated prevalence of 1 to 3 cases per million. Therefore, the increasing prevalence of primary hyperoxaluria is contributing to the growth of the Oxlumo market.

Major companies operating in the Oxlumo market are focusing on in vivo gene-editing therapies, such as single-dose CRISPR-based treatments, to inactivate the HAO1 gene, which encodes glycolate oxidase and helps reduce oxalate production in the liver. In this context, in vivo gene-editing therapy refers to a treatment in which a gene editor (e.g., CRISPR/Cas nuclease) is directly delivered into a patient’s hepatocytes, commonly via lipid nanoparticles (LNPs), to edit the target gene within the body. This approach has the potential to offer a durable or even one-time cure. For instance, in August 2024, YolTech Therapeutics, a China-based gene-editing company, administered the first patient dose of YOLT-203, an in vivo gene-editing therapy for primary hyperoxaluria type 1 (PH1). YOLT-203 utilizes YolTech’s proprietary YolCas12 editor, delivered via LNP-mRNA, and is designed to target the HAO1 gene in hepatocytes. Key features of YOLT-203 include its single-dose, potentially curative design, high-efficiency precision editing using YolTech’s HEPDONE-evolved Cas12 editor, and targeted delivery via lipid nanoparticles, which enable liver-specific uptake.

Major companies operating in the oxlumo market are Alnylam Pharmaceuticals Inc.

North America was the largest region in the oxlumo market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the oxlumo market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the oxlumo market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Tariffs are influencing the oxlumo market by increasing costs related to imported nucleic acid materials, specialized formulation equipment, injection delivery systems, and cold-chain logistics services. These effects are most significant in regions such as North America and Europe, where advanced RNA-based drug manufacturing relies on globally sourced inputs. Elevated tariffs can increase treatment costs and strain healthcare budgets for rare disease management. At the same time, tariffs are supporting domestic biopharmaceutical manufacturing initiatives, encouraging regional supply chain localization, and accelerating investments in local RNA therapeutics production capabilities.

The oxlumo market research report is one of a series of new reports that provides oxlumo market statistics, including oxlumo industry global market size, regional shares, competitors with a oxlumo market share, detailed oxlumo market segments, market trends and opportunities, and any further data you may need to thrive in the oxlumo industry. This oxlumo market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Oxlumo (lumasiran) is a medication used to treat primary hyperoxaluria type 1 (PH1), a rare genetic disorder that causes excessive oxalate production, leading to kidney damage. It works by inhibiting the enzyme HOGA1, which plays a role in oxalate production. Oxlumo helps prevent kidney stones and kidney failure by reducing oxalate levels in the body. It is administered via subcutaneous injection.

The main clinical indications for Oxlumo include primary hyperoxaluria type 1 (PH1), kidney stones, and end-stage renal disease (ESRD). Primary hyperoxaluria type 1 (PH1) is treated with Oxlumo, which reduces liver oxalate production, preventing kidney damage and failure. Oxlumo is distributed through various channels, such as retail pharmacies and online pharmacies, and is used by a range of end users, including pediatric and adult patients.

The oxlumo market consists of sales of oxlumo (lumasiran) injections. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.